A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

NCT06228326 · tracked via the Priya Life Science USA tracker

Sponsor

Krystal Biotech, Inc

Phase

Phase 1/2

Started

2024-04-17

Last updated

2025-10-24

Condition(s) studied

Lung Cancer, Non-small CellLung Cancer MetastaticSolid Tumor, AdultAdvanced CancerLung Cancer (NSCLC)

Investigational drug(s) / intervention(s)

KB707 →Pembrolizumab (KEYTRUDA®) →ChemotherapyDocetaxel →

KB707: Genetically modified herpes simplex type 1 virus

Pembrolizumab (KEYTRUDA®): PD-1 immune checkpoint inhibitor

Chemotherapy: SOC chemotherapy

Docetaxel: SOC chemotherapy

Study summary

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies.

This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707.

Monotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The dose escalation phase (Cohorts 1 and 2) evaluated KB707 monotherapy using a standard 3+3 design, followed by a dose expansion phase (Cohort 4) to further evaluate the selected dose. Subjects received inhaled KB707 weekly for three weeks, then every three weeks. The dose escalation portion of the study is now complete, and the selected dose is being evaluated in the expansion phase.

Combination regimens with a selected (fixed) dose of KB707 are being evaluated in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 are receiving inhaled KB707 once every 2 weeks (q2w), delivered in combination with Keytruda once every 6 weeks. Subjects in Cohort 7 are receiving inhaled KB707 in combination with docetaxel once every 3 weeks.

All subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Key Inclusion Criteria: * Age 18 years or older at the time of informed consent * Life expectancy \>12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Have at least one measurable lung lesion per RECIST v1.1 at Screening * Cohorts 1 through 4 only: Histologically confirmed diagnosis of advanced solid tumor malignancy affecting the lungs and the individual has progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or has no standard of care therapy. * Cohorts 5, 6, and 7 only: (1) Histologically or cytologically confirmed diagnosis of stage 3 or 4 NSCLC, as per American Joint Committee on Cancer (AJCC) staging system (8th edition) and (2) Subject must meet the following criteria of prior lines of therapy: 1. Subject has previously received no more than one line of prior immune checkpoint inhibitor (ICI) with or without platinum-based chemotherapy, or no more than two prior lines of therapy when given the ICI and platinum-based chemotherapy sequentially as two separate lines. 2. Subjects with an actionable mutation (e.g., EGFR, KRAS, ALK, or ROS1 genomic alteration), are permitted to have received one additional line of approved targeted therapy. Key Exclusion Criteria: * Not fully recovered from prior surgery or radiotherapy, including all radiation-related toxicities * The subject is pregnant, nursing, or plans to become pregnant during study treatment and through three months after the last dose of KB707 * Have known history of positive human immunodeficiency virus (HIV 1/2) * Cohorts 5, 6, and 7 only: 1. Subject has a known additional malignancy that is progressing or requires active treatment 2. Subject has active brain metastases or leptomeningeal metastases 3. Prior anti-PD-1/PD-L1 therapy was intolerable and required discontinuation of treatment 4. Subject has active, known, or suspected autoimmune disease requiring systemic treatment 5. Subject has known acute or chronic hepatitis 6. Subject has active pneumonitis or history of ICI-induced pneumonitis that required steroids

Primary outcome measure(s)

To evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE) — up to 36 months
Percentage of subjects with treatment-related AEs as assessed by NCI-CTCAE v5

Trial sites (14)

Facility	City	Region	Status
XCancer Research Network/Dothan Hematology & Oncology	Dothan	Alabama	Recruiting
HonorHealth Research Institute	Scottsdale	Arizona	Recruiting
Precision NextGen Oncology	Beverly Hills	California	Recruiting
Emad Ibrahim MD Inc	Redlands	California	Recruiting
BRCR Global	Weston	Florida	Recruiting
IU Simon Comprehensive Cancer Center	Indianapolis	Indiana	Terminated
Ochsner/MD Anderson Cancer Center	New Orleans	Louisiana	Recruiting
Henry Ford Health	Detroit	Michigan	Recruiting
Gabrail Cancer Center Research	Canton	Ohio	Recruiting
Cleveland Clinic	Cleveland	Ohio	Recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	Terminated
Sarah Cannon Research Institute	Nasville	Tennessee	Recruiting
Renovatio Clinical	El Paso	Texas	Terminated
Renovatio Clinical	The Woodlands	Texas	Terminated

More Krystal Biotech, Inc. trials in the USA

A Study Assessing KB407 for the Treatment of Cystic Fibrosis Recruiting

A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency Recruiting

A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey Disease Recruiting

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB) Recruiting

Long-Term Follow-up Protocol Recruiting

Other trials for the same condition

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer Active, not recruiting

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) Active, not recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06228326 on ClinicalTrials.gov ↗ ← All trials in the USA